Conmed (CNMD) Cost of Revenue (2010 - 2026)

Conmed has reported Cost of Revenue for 17 years, with the latest figure at $133.6 million in Q1 2026.

• For the quarter ending Q1 2026, Cost of Revenue fell 6.9% year-over-year to $133.6 million; the trailing twelve-month figure through Mar 2026 stood at $614.3 million (up 6.44% YoY), and the FY2025 full-year result was $624.2 million, up 8.76% from the prior year.
• Cost of Revenue for Q1 2026 stood at $133.6 million, down from $154.9 million in the prior quarter.
• The five-year high for Cost of Revenue was $171.8 million in Q3 2025, with the low at $106.3 million in Q1 2022.
• Historically, Cost of Revenue has averaged $139.7 million across 5 years, with a median of $140.3 million in 2024.
• Annual changes were most pronounced in 2023 — Cost of Revenue surged 31.8% — and 2026, when it slipped 6.9%.
• Conmed's Cost of Revenue stood at $119.0 million in 2022, then increased by 21.73% to $144.9 million in 2023, then rose by 1.88% to $147.6 million in 2024, then gained by 4.95% to $154.9 million in 2025, then retreated by 13.76% to $133.6 million in 2026.
• The last three Cost of Revenue figures came in at $133.6 million (Q1 2026), $154.9 million (Q4 2025), and $171.8 million (Q3 2025), per Business Quant data.